Faslodex
(Fulvestrant)ApprovedSmall molecule
Fulvestrant is used to treat hormone receptor-positive breast cancer in postmenopausal women. It works by blocking estrogen receptors on cancer cells, preventing estrogen from fueling their growth.[2] Faslodex is currently approved and in use across 46 indications[4].[1]
Faslodex is one of 680 small molecule programs targeting Bone Metastasis. It is currently in Approved.
46
Indications
380
Total Trials
58
Active Trials
679
Competitors
3
FDA Applications
NDA/BLA/ANDA regulatory filings
3
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 45 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Faslodex
FFresenius Kabi Oncology Ltd.
Approved
Halaven
EisaiPreclinical
Tecentriq
RochePreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Zinecard
CChildren's Oncology Group
Preclinical
Effexor
WWyeth-Lederle Vaccines
Preclinical
Chirocaine
PPurdue Pharma LP
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Apatinib Mesylate
BBukwang Pharmaceutical
Preclinical
Vit D
PPost Graduate Institute of Medical Education and Research, Chandigarh
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer133 trials
Show 130 more trials
Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer
Completed·—·Phase 2·NCT04352777·18 enrolled
Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor
Recruiting·—·Phase 2·NCT05933395·135 enrolled
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
Completed·—·Phase 2·NCT01560416·50 enrolled
Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer
Completed·—·Phase 2·NCT00146601·35 enrolled
Effectiveness and Safety of Fulvestrant in Postmenopausal Women With Advanced Breast Cancer HR+, HER2-
Unknown status·—··NCT05140655·40 enrolled
To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer
Active, not recruiting·
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT05365178·432 enrolled
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT05365178·432 enrolledA Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer
Not yet recruiting·
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT06941142·382 enrolled
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT06941142·382 enrolled
The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer
Unknown status·—·Phase 2·NCT02072512·180 enrolled
Advanced Solid Tumors5 trials
Ovarian Cancer4 trials
Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer
Terminated·—·Phase 1·NCT03294694·33 enrolled
Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer
Recruiting·—·Phase 2·NCT05113368·31 enrolled
Show 1 more trial
Endometrial Cancer3 trials
41 more indications
Efficacy and Safety2 trials
Efficacy and Safety of 500mg of Fulvestrant
Active, not recruiting·—·Phase 2·NCT00585507·40 enrolled
Postmenopausal Women2 trials
Growth2 trials
Endocrine Therapy2 trials
Palbociclib After CDK and Endocrine Therapy (PACE)
Active, not recruiting·—·Phase 2·NCT03147287·220 enrolled
Prostate Cancer2 trials
Clinical Trial2 trials
Combination Therapy2 trials
Non-Small Cell Lung Cancer2 trials
Patients With Advanced Solid Tumors2 trials
Ductal Carcinoma in Situ1 trial
Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast
Unknown status·—·N/A·NCT00126464·100 enrolled
Pancreatic Cancer1 trial
ART1 trial
Bone Metastasis1 trial
Urothelial Cancer1 trial
Patients With Solid Tumors1 trial
Ptosis1 trial
Recurrent Ovarian Epithelial Cancer1 trial
Gynecologic Cancer1 trial
Pulmonary Arterial Hypertension1 trial
Effectiveness1 trial
Steroid1 trial
Advanced Solid Malignancies1 trial
Solid Tumors1 trial
Prevention1 trial
Endometrial Carcinoma1 trial
Female1 trial
Breast Ductal Carcinoma in Situ1 trial
Cancers1 trial
Overall Survival1 trial
Single Ascending Dose1 trial
Advanced1 trial
Unspecified3 trials
Regulatory
FDA Approval Timeline[5]
Apr 25, 2002
FASLODEX
NDA NDA021344
May 20, 2019
FULVESTRANT
NDA NDA210326
Aug 19, 2019
FULVESTRANT
NDA NDA210063
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Faslodex drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Fulvestrant. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Estrogen Receptor Alpha Antagonist; Estrogen Receptor Degrader[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- FFresenius Kabi Oncology Ltd.